PanGen Biotech Inc. (222110.KQ)
- Previous Close
5,700.00 - Open
5,700.00 - Bid 5,600.00 x --
- Ask 5,650.00 x --
- Day's Range
5,530.00 - 5,870.00 - 52 Week Range
3,750.00 - 7,770.00 - Volume
40,456 - Avg. Volume
25,542 - Market Cap (intraday)
72.514B - Beta (5Y Monthly) 0.00
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.
www.pangen.comRecent News: 222110.KQ
View MorePerformance Overview: 222110.KQ
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 222110.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 222110.KQ
View MoreValuation Measures
Market Cap
72.01B
Enterprise Value
61.40B
Trailing P/E
69.51
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.47
Price/Book (mrq)
2.89
Enterprise Value/Revenue
4.18
Enterprise Value/EBITDA
21.97
Financial Highlights
Profitability and Income Statement
Profit Margin
6.43%
Return on Assets (ttm)
2.49%
Return on Equity (ttm)
5.04%
Revenue (ttm)
14.67B
Net Income Avi to Common (ttm)
943.69M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
11.43B
Total Debt/Equity (mrq)
3.29%
Levered Free Cash Flow (ttm)
228.45M